Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | NQO1 | P15559 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16288430 | 0.80 | NQO1 (0.56) | ESR1AHRNQO1KDM4ESMN1; SMN2 | |
| SCHEMBL12814340 | 0.77 | CYP1A1 (0.56) | ESR1AHRKDM4EALDH1A1ABL1 | |
| SCHEMBL16954674 | 0.77 | ESR1 (0.47) | ESR1AHRNQO1KDM4ESMN1; SMN2 | |
| SCHEMBL272248 | 0.76 | EGFR (0.53) | ESR1AHRKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL1683212 | 0.75 | NQO1 (0.65) | ESR1AHRNQO1KDM4ESMN1; SMN2 | |
| SCHEMBL6197483 | 0.72 | ESR1 (0.47) | ESR1AHRNQO1KDM4ESMN1; SMN2 | |
| SCHEMBL273282 | 0.72 | ALDH1A1 (0.47) | ESR1AHRNQO1KDM4ESMN1; SMN2 | |
| SCHEMBL6197489 | 0.72 | ESR1 (0.47) | ESR1AHRNQO1KDM4ESMN1; SMN2 | |
| SCHEMBL12378478 | 0.72 | ALDH1A1 (0.54) | ESR1AHRSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL10709235 | 0.71 | KMT2A (0.49) | ESR1AHRNQO1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894048-B2 | Antitumor drug for intermittent administration of FGFR inhibitor | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-19 | — | — | US | disclosed |
| US-10835536-B2 | Therapeutic agent for FGFR inhibitor-resistant cancer | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-11-17 | — | — | US | disclosed |
| EP-3023101-B1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | TAIHO PHARMACEUTICAL CO LTD (JP) | 2020-08-19 | — | — | EP | disclosed |
| US-20190183897-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-06-20 | — | — | US | disclosed |
| EP-3023100-B1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | TAIHO PHARMACEUTICAL CO LTD (JP) | 2019-03-13 | — | — | EP | disclosed |
| US-20190015417-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-01-17 | — | — | US | disclosed |
| US-10124003-B2 | Therapeutic agent for FGFR inhibitor-resistant cancer | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-11-13 | — | — | US | disclosed |
| US-20160193210-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| EP-3023100-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| EP-3023101-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-20160136168-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-9108973-B2 | 3,5-disubstituted alkynylbenzene compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20140343035-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO.,LTD. (JP) | 2014-11-20 | — | — | US | disclosed |
| EP-2657233-B1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2014-08-27 | — | — | EP | disclosed |
| EP-2657233-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2013-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183897-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | FGFR1, FGFR3, FGFR2 | ESR1 2865/4885AHR 402/4885NQO1 3269/4885 |
| US-20190015417-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | FGFR1, FGFR3, FGFR4 | ESR1 3230/4885AHR 246/4885NQO1 1296/4885 |
| US-20160136168-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | FGFR1, FGFR3, FGFR4 | ESR1 3230/4885AHR 246/4885NQO1 1296/4885 |
| US-20160193210-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | FGFR1, FGFR3, FGFR2 | ESR1 2252/4885AHR 232/4885NQO1 2985/4885 |
| US-10894048-B2 | Antitumor drug for intermittent administration of FGFR inhibitor | FGFR1, FGFR3, FGFR2 | ESR1 2865/4885AHR 402/4885NQO1 3269/4885 |
| US-20140343035-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | NFXL1, ZFX, CXXC5 | ESR1 1887/4885AHR 803/4885NQO1 1834/4885 |
| US-10835536-B2 | Therapeutic agent for FGFR inhibitor-resistant cancer | FGFR1, FGFR3, FGFR4 | ESR1 3230/4885AHR 246/4885NQO1 1296/4885 |
| US-10124003-B2 | Therapeutic agent for FGFR inhibitor-resistant cancer | FGFR1, FGFR3, FGFR4 | ESR1 3230/4885AHR 246/4885NQO1 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.